Drug
Carotuximab clinical trials
Also written TRC105.
- studies test it
- 25
- open now
- 2
- in phase 3
- 1
- first study started
- 2007
Keep track of what changes. Save the carotuximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
25 studies that test it; most in 2011 (6)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 3 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 18
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 11
Tracon Pharmaceuticals Inc. (13) · National Cancer Institute (NCI) (7) · University of Alabama at Birmingham (2) · Santen Inc. (1) · Edwin Posadas, MD (1) · Karen Reckamp, MD, MS (1)
Often tested with
Tested in the same studies.
Bevacizumab (4) · Sorafenib (2) · Letrozole (1) · Everolimus (1) · Ranibizumab (1) · Nivolumab (1) · Pazopanib (1) · Capecitabine (1)
Studies
Open first, then newest update. How each study uses carotuximab is read from its arms, and is right about nine times in ten.
Testing it · 25
- Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancRecruitingPhase 2Edwin Posadas, MDNCT05534646Written as Carotuximab
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingPhase 1Karen Reckamp, MD, MSNCT05401110Written as Carotuximab
- Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast CancerCompletedPhase 1/2University of Alabama at BirminghamNCT02520063Written as TRC105
- Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsCompletedPhase 2Santen Inc.NCT03211234Written as 2.0 mg DE-122 Injectable Solution + Lucentis
- A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung CancerCompletedPhase 1University of Alabama at BirminghamNCT02429843Written as TRC105
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell CarcinomaTerminatedPhase 1/2Tracon Pharmaceuticals Inc.NCT01806064Written as TRC105 and Axitinib
- Trial of TRC105 and Sorafenib in Patients With HCCCompletedPhase 1/2Tracon Pharmaceuticals Inc.NCT02560779Written as Carotuximab (TRC105)
- Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLCCompletedPhase 1Tracon Pharmaceuticals Inc.NCT03181308Written as Carotuximab (TRC105)
- A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue SarcomaCompletedPhase 1/2Tracon Pharmaceuticals Inc.NCT01975519Written as TRC105 and Pazopanib
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced AngiosarcomaCompletedPhase 3Tracon Pharmaceuticals Inc.NCT02979899Written as TRC105
- Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLCCompletedPhase 1Tracon Pharmaceuticals Inc.NCT03780010Written as TRC105
- Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)TerminatedPhase 2Tracon Pharmaceuticals Inc.NCT02664961Written as TRC105
- A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With GlioblastomaCompletedPhase 2Tracon Pharmaceuticals Inc.NCT01564914Written as TRC105
- TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory ChoriocarcinomaCompletedPhase 2Tracon Pharmaceuticals Inc.NCT02396511Written as TRC105
- Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast CancerCompletedPhase 1/2Tracon Pharmaceuticals Inc.NCT01326481Written as TRC105
- Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaCompletedPhase 2Tracon Pharmaceuticals Inc.NCT01381861Written as Carotuximab (TRC105)
- Sorafenib and TRC105 in Hepatocellular CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01306058Written as TRC 105
- Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is IndicatedCompletedPhase 1Tracon Pharmaceuticals Inc.NCT01332721Written as TRC105 and Bevacizumab
- Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT01727089Written as Anti-Endoglin Chimeric Monoclonal Antibody TRC105
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedPhase 1/2National Cancer Institute (NCI)NCT01648348Written as Anti-Endoglin Chimeric Monoclonal Antibody TRC105
See all 25 studies that test carotuximab →
Given in every arm · 1 — carotuximab is usual care beside what is tested
Codes
What other systems call carotuximab · ClinicalTrials.gg INT006257
- MeSH (NLM) C579557carotuximabOne source NLM
- UNII (FDA) YB2EWE6139CAROTUXIMABConfirmed FDA, NLM
- NCI Thesaurus C74010CarotuximabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579557 | carotuximab | One source NLM |
| UNII (FDA) | YB2EWE6139 | CAROTUXIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C74010 | Carotuximab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.